FCS

Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...

PASADENA, Calif., August 17, 2026 Arrowhead Pharmaceuticals, Inc. announced that people living with familial chylomicronaemia syndrome (FCS) in Germany...

Pasadena, California | April 24, 2026 Arrowhead Pharmaceuticals has achieved a major regulatory milestone as the Committee for Medicinal...